摘要:
The subject invention pertains to a method and device for implementing a dynamic End of Discharge Voltage (EODV) for rechargeable batteries and battery packs (batteries/packs). This dynamic EODV can be adjusted based on, for example, environment, operating conditions, temperature, residual capacity, cell chemistry, cell size, form factor, discharge rate, and/or the number of charge/discharge cycles the battery has undergone. The subject invention can provide for enhanced run time from each discharge cycle of the battery/pack. In addition, the subject invention can provide for more accurate save-to-disk alarms, while ensuring adequate energy for the actual save to disk operation. Furthermore, the subject invention can also extend the useful life of the battery/pack.
摘要:
A process for fixed bed sweetening of petroleum distillates using halogenating metal phthalocyanine as a catalyst comprising impregnating the catalyst on activated charcoal bed by circulating alcoholic alkaline solution of the catalyst through charcoal bed till colorless bed solution is obtained in the effluent, passing the petroleum distillate through the said catalyst loaded charcoal bed along with air or oxygen at a temperature and pressure with liquid hourly space velocity with continuous or intermittent injection of alkali solution such as sodium hydroxide of concentration to obtain the desired low mercaptan level petroleum distillates. The alkaline solution used is selected from methanolic and ethanolic solution of sodium hydroxide. The halogenated metal phthalocyanine catalyst used is selected from dichloro cobalt phthalocyanine and dibromo cobalt phthalocyanine. The petroleum fraction used is selected from diesel, kerosene and FCC gasoline.
摘要:
A process for the preparation of a supported catalyst comprising a Halogenated Phthalocyanine of cobalt, iron or manganese of formula 1 which comprises: mixing a phthalocyanine of cobalt, iron or manganese with a halogenating agent in a stoichiometric ratio ranging between 1:1 to 1:20 optionally in an inert organic solvent, refluxing or heating and stirring for a time period ranging between 1-6 hrs, distilling the excess halogenating agent from the mixture, filtering and washing the residual mass by known method to obtain the desired halogenated phthalocyanine and impregnating a support material with the desired halogenated phthalocyanine.
摘要:
The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.
摘要:
An electrochemical cell having a bimodal positive electrode, a negative electrode of an alkali metal, and a compatible electrolyte including an alkali metal salt molten at the cell operating temperature. The positive electrode has an electrochemically active layer of at least one transition metal chloride at least partially present as a charging product, and additives of bromide and/or iodide and sulfur in the positive electrode or the electrolyte. Electrode volumetric capacity is in excess of 400 Ah/cm.sup.3 ; the cell can be 90% recharged in three hours and can operate at temperatures below 160.degree. C. There is also disclosed a method of reducing the operating temperature and improving the overall volumetric capacity of an electrochemical cell and for producing a positive electrode having a BET area greater than 6.times.10.sup.4 cm.sup.2 /g of Ni.
摘要:
The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.
摘要:
An electrochemical cell with a positive electrode having an electrochemically active layer of at least one transition metal chloride. A negative electrode of an alkali metal and a compatible electrolyte including an alkali metal salt molten at cell operating temperature is included in the cell. The electrolyte is present at least partially as a corrugated .beta." alumina tube surrounding the negative electrode interior to the positive electrode. The ratio of the volume of liquid electrolyte to the volume of the positive electrode is in the range of from about 0.1 to about 3. A plurality of stacked electrochemical cells is disclosed each having a positive electrode, a negative electrode of an alkali metal molten at cell operating temperature, and a compatible electrolyte. The electrolyte is at least partially present as a corrugated .beta." alumina sheet separating the negative electrode and interior to the positive electrodes. The alkali metal is retained in a porous electrically conductive ceramic, and seals for sealing the junctures of the electrolyte and the adjacent electrodes at the peripheries thereof.
摘要:
The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.
摘要:
The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.
摘要:
The invention relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.